Fundraising Fox
/Companies
Sign in

Tallac Therapeutics

Burlingame, US · Founded 2018 · 5 known investors

Find your way into Tallac Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

63 people can intro you to Hong

Ask Luke Horton to introduce you to Hong Wan

You →Luke · together at Wyeth →Hong

Sign up to find every way you can get introduced to Tallac Therapeutics

  • Your email: who you already know at Tallac Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Tallac Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications. The company has two programs currently in clinical trials.

BiotechHealthtechMedical Devices

Founders & leadership

Tallac Therapeutics was founded in 2018 by Hong Wan.

HWHong Wan
Hong WanPresident, Chief Executive Officer and Co-FounderHong Wan is an executive officer and director at Tallac Therapeutics, a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates for oncology. He brings experience as a scientist and drug developer.

Board

RG
Ran GengBoard director
MC
Michael CarusiBoard director
IC
Isaac ChengBoard director
CB
Christine BrennanBoard director
CGCorey Goodman
Corey GoodmanBoard directorCo-founder and Managing Partner at venBio Partners
JPJaume Pons
Jaume PonsBoard directorVenture Partner at venBio Partners

Investors · 5

MRL Ventures Fundlisted by MRL Ventures FundCambridge · $25M

How we know: MRL Ventures Fund's portfolio page · funding news · Not right? Tell us

venBio Partnerslisted by venBio PartnersSan Francisco

How we know: a partner's Signal profile · board seat on SEC Form D · funding news · the VCSheet dataset · Not right? Tell us

Matrix Partners ChinareportedBeijing

How we know: funding news · Not right? Tell us

venBio Global StrategicinferredSan Francisco

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$61.6M disclosed across 1 round · 2020

▶$61.6MraisedJul 2021 · 12 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Ran GengDirector
  • Michael CarusiDirector
  • Isaac ChengDirector
  • Christine BrennanDirector
  • Corey GoodmanDirector
  • Hong WanExecutive Officer, Director
  • Jaume PonsDirector
Offering amount
$61.6M
Amount sold
$61.6M
First sale
Jun 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Tallac Therapeutics went on to found or lead other companies.

Corey GoodmanDirectorFounded Alx OncologyJaume PonsDirectorFounded Alx Oncology

Related companies · 4

Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
RelayRelay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
TrisaluslifesciTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.

Companies working in the same space as Tallac Therapeutics.

In the news

Horizon Technology Finance Provides $15 Million Venture Loan Facility to Tallac Therapeuticsprnewswire.com · Aug 2023

Frequently asked questions

What does Tallac Therapeutics do?
Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications. The company has two programs currently in clinical trials.
Who founded Tallac Therapeutics?
Tallac Therapeutics was founded by Hong Wan in 2018.
Who are Tallac Therapeutics's investors?
Tallac Therapeutics's investors include Lightstone Ventures, MRL Ventures Fund, venBio Partners, Matrix Partners China, venBio Global Strategic.
How much funding has Tallac Therapeutics raised?
Tallac Therapeutics has disclosed $61.6M raised across 1 round.
Where is Tallac Therapeutics headquartered?
Tallac Therapeutics is headquartered in Burlingame, US.